Lilly to Help Diabetes Patients

Eli Lilly (NYSE:LLY) says it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak.

The new co-pay scheme covers most of Lilly’s insulins, including widely-used Humalog injection, and can be purchased by people with commercial insurance as well as those without insurance.

The Indianapolis-based Lilly says the savings can be obtained by calling the Lilly Diabetes Solution Center. Representatives at the Solution Center will help people with diabetes obtain a card in the most convenient way for them, including through email or the U.S. mail.

Representatives at the Solution Center can also direct people to affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.

According to company president Mike Mason, "Too many people in the U.S. have lost their jobs because of the COVID-19 crisis, and we want to make sure no one goes without their Lilly insulin.

"We've been providing affordability solutions for a long time, but more is needed to help people during this unprecedented period. People with commercial insurance, as well as those without insurance at all, are eligible, and the process is quick and simple. We want people who need help to call us."

Shares gained 35 cents to $141.57.

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks